Background. Although vaccine rollout for COVID‐19 has been effective in some countries,
there is still an urgent need to reduce disease transmission and severity. We recently carried …

World Health Organization (WHO) first declared coronavirus disease 2019 (COVID-19) as a
pandemic in March 2020, and now, six months after that, the number of positive and death …

This content has been supplied by the author (s). It has not been vetted by BMJ Publishing
Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or …

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection. The infection started as an outbreak of pneumonia …

COVID-19 has proved to be a serious, and consequential disease that has affected millions
of people globally. Previously, the adverse effects of proton pump inhibitors (PPI) have been …

We read with interest the study by Luxenburger et al.[1] which reported that patients with
coronavirus disease 2019 (COVID-19) receiving proton pump inhibitors (PPIs) were at …

Aims One of the comorbidities associated with severe outcome and mortality of COVID-19 is
dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of …

Purpose Previously, we have reported potential clinical benefits with the use of statins in
patients with coronavirus disease 2019 (COVID-19) in a meta-analysis, where there was a …

Background & Aims Proton pump inhibitor (PPI) use has been associated with increased risk
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered the
causative pathogen of coronavirus disease 2019 (COVID-19) and has become an …